Ebastine plus docetaxel for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests if combining the allergy drug ebastine with the chemotherapy docetaxel can help men with advanced prostate cancer that has stopped responding to hormone therapy. It may offer a new treatment option for those whose cancer is still growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of prostate cancer called adenocarcinoma, but not a rare small-cell type.
- Your testosterone levels must be very low (from surgery or hormone therapy), and you need to stay on that therapy.
- Your cancer must have grown despite previous treatments, shown by rising PSA, new bone spots, or new tumors on scans.
- You must be at least 18 years old, with a life expectancy of 3 months or more, and be in good enough physical health to be up and about (ECOG 0-1).
- Your blood counts, liver, and kidney function must be within acceptable ranges.
- You cannot have had major stomach or bowel surgery, active infections, or certain medical conditions that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding darolutamide to either docetaxel or cabazitaxel helps treat men with advanced, progressing prostate cancer. It’s for cancers that have already grown despite hormone-blocking tablets (ARSi).
This trial tests a new drug called BNT324 against the standard chemotherapy docetaxel for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the new treatment can help control the cancer better.
This trial tests a combination of two chemotherapy drugs (carboplatin and docetaxel) for men whose prostate cancer has spread and has specific changes in DNA repair genes. It aims to see if this treatment can help when other hormone therapies have stopped working.
This study combines an immunotherapy drug called sipuleucel-T (which boosts your immune system to fight cancer) with a high-dose testosterone treatment called bipolar androgen therapy. The goal is to see if this combination can help men with advanced prostate cancer that is not responding to usual hormone therapy.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests a new drug combination for men with advanced prostate cancer that has stopped responding to initial hormone therapy. The treatment targets low-oxygen areas in tumors, which may help slow cancer growth.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.